Back to Results
First PageMeta Content
Pharmacology / Food and Drug Administration / Drug discovery / Pharmaceutical industry / Prescription Drug User Fee Act / Orphan drug / Orphan Drug Act / Pharmaceutical marketing / Biotechnology / Pharmaceutical sciences / Pharmaceuticals policy / Health


RepliGen Sandford D. Smith President and Chief Executive 01ficer Repligen Corporation
Add to Reading List

Document Date: 2014-06-13 22:34:43

Open Document

File Size: 3,51 MB

Share Result on Facebook

City

Washington / D.C. / Cambridge / Boston / /

Company

Wall Street Journal / PMA companies / RepliGen Sandford D. Smith / Ernst & Young / Industry / Repligen Corporation / /

Country

United States / /

Currency

pence / USD / /

Event

FDA Phase / /

Facility

A Tufts University / One Financial Center / Repligen Corporation One Kendall Square Building / /

/

IndustryTerm

biopharmaceutical / biotechnology / pharmaceutical / /

Organization

Congress / National Institute of Health / White House / White House Washington / FDA / Tufts University / Medicare / /

Person

Carol H. Rasco / Metzenbaum / Mark Gearan / Carol Rasco May / /

/

Position

VICE PRESIDENT BlorHERAPEUTICS GENZYME COr / leader / President / Chief Executive / Secretary of Economic Affairs with fondness and nostalgia / President for Domestic policy / SENfoR VICE PRESIDENT / Domestic Policy Advisor / Private / Assistant / Officer / ior Advisor / Massachusetts Biotechnology Council Dl6461.1 / President and Chief Executive / /

Product

FY1993 / /

ProvinceOrState

D.C / Massachusetts / /

PublishedMedium

Wall Street Journal / /

Technology

alpha / biopharmaceuticals / Biotechnology / /

SocialTag